Related Experiment Videos
Delivery of endostatin in experimental cancer therapy
Dag R Sorensen1, Tracy-Ann Read
1Department of Comparative Medicine, Rikshospitalet, University of Oslo, Norway. d.r.sorensen@labmed.uio.no
Abstract:
Endostatin, the 20 kDa C-terminal fragment of collagen XVIII, has been shown to be an effective inhibitor of tumour angiogenesis and growth in different experimental systems and is currently in Phase II/III clinical trials. One challenging aspect of anti-angiogenic treatment is the mode of delivery of the active compound. In this paper we review some of the basic knowledge of endostatin and look specifically into the different possible ways in which endostatin may be administered.
Insights
Endostatin, a collagen fragment, inhibits tumor growth and angiogenesis. This review explores various administration methods for this promising anti-cancer therapy.
Area of Science:
- Biochemistry
- Oncology
- Pharmacology
Background:
- Endostatin is a 20 kDa C-terminal fragment derived from collagen XVIII.
- It demonstrates significant inhibition of tumor angiogenesis and growth in experimental models.
- Endostatin is currently undergoing Phase II/III clinical trials for cancer treatment.
Purpose of the Study:
- To review fundamental knowledge regarding endostatin.
- To specifically examine diverse administration strategies for endostatin therapy.
Main Methods:
- Literature review of endostatin's properties and anti-angiogenic mechanisms.
- Analysis of existing and potential drug delivery systems for endostatin.
Main Results:
- Endostatin's efficacy as an anti-angiogenic agent is established.
- Various delivery methods present unique challenges and opportunities for clinical application.
Conclusions:
- Effective administration is crucial for successful endostatin-based anti-angiogenic therapy.
- Further research into optimized delivery systems is warranted to maximize therapeutic potential.